Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India

Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India — one of the world’s most ethnically diverse countries.